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ABSTRACT
In this thesis, we are interested in finding the best drugs that can be repurposed
for the disease and able to find the adverse effects such drugs that are FDA-Approved.
Developing an effective drug can be a time-consuming and expensive crucible method.
Network-based machine learning methods are used for predicting a given drug for
A that can be used for B. It aims at finding new indications for already existing
drugs and therefore increases the available therapeutic choices at a fraction of the
cost of new drug development. The perturbation gene expression data corresponding
to the MCF7 cell line was extracted from the National Institute of Health’s (NIH),
Library of Integrated Network-Based Cellular Signatures (LINCS) dataset. Using the
Louvain community detection algorithm on the breast network data and we obtain
14 communities. Then the correlation analysis was performed on each of the drug
network data and the corresponding disease network communities. Finally, we do the
Hungarian Algorithm and Edmond’s matching Algorithm to obtain the best-suited
drug that could be repurposed for breast cancer disease, and using reporting odds
ratio method, we could find out the adverse effects of drugs approved by the FDA.

IV

DEDICATION
I dedicate this thesis to my beloved parents for their endless love, support and
encouragement.

V

ACKNOWLEDGEMENTS
First and foremost, I would like to thank God, the Almighty, for His blessings to
complete my thesis work successfully.
I would like to thank my supervisor, Dr.Alioune Ngom, for his exceptional guidance,
patience, and constant support. This thesis would not have been possible without
this ideas and suggestions.Thank you for being a consistent trainer. I have greatly
benefited from his immense knowledge and it has been such an honor for me to work
under his supervision.
I would also like to thank my external reader Dr.Myron Hlynka and internal reader
Dr.Dima Alhadidi for being a part of this thesis. Their feedback and comments have
helped in further improvement of this thesis.
Finally, I would like to thank all my friends and family especially Jerin K Tom who
has been a source of constant moral support during my thesis process.

VI

TABLE OF CONTENTS
DECLARATION OF ORIGINALITY

III

ABSTRACT

IV

DEDICATION

V

ACKNOWLEDGEMENTS

VI

LIST OF TABLES

IX

LIST OF FIGURES

X

LIST OF ABBREVIATIONS
1

2

3

XII

Introduction
1.1 Drug . . . . . . . . . . . . . . . . . . . . .
1.2 Drug Repurposing and Drug Repositioning
1.2.1 Drug Repurposing . . . . . . . . .
1.2.2 Drug Repostioning . . . . . . . . .
1.3 Methods . . . . . . . . . . . . . . . . . . .
1.4 Traditional drug discovery . . . . . . . . .
1.5 Computational drug discovery . . . . . . .
1.6 Problem Statement . . . . . . . . . . . . .
1.7 Thesis Motivation . . . . . . . . . . . . . .
1.8 Thesis Contribution . . . . . . . . . . . . .
1.9 Thesis Organization . . . . . . . . . . . . .

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.

1
2
3
4
5
5
7
8
9
10
10
10

Literature Review
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.1.1 A Network Approach for Computational Drug Repositioning .
2.1.2 A new computational drug repurposing method using established disease-drug pair knowledge . . . . . . . . . . . . . . . .
2.1.3 A novel computational approach for drug repurposing using
systems biology . . . . . . . . . . . . . . . . . . . . . . . . . .
2.1.4 Drug repositioning for cancer therapy based on large-scale druginduced transcriptional signatures . . . . . . . . . . . . . . . .
2.1.5 Breaking the paradigm: Dr Insight empowers signature free,
enhanced drug repurposing . . . . . . . . . . . . . . . . . . . .

12
12
12

Proposed Methods
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.1 Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.2 Why Breast Cancer? . . . . . . . . . . . . . . . . . . . . . . .

16
16
16
16

VII

13
14
14
15

3.2

3.3

3.4

4
5

Datasets . . . . . . . . . . . . . . . . . . . . . . . . . .
3.2.1 Reactive Stroma of Breast and Prostate Cancer
3.2.2 LINCS . . . . . . . . . . . . . . . . . . . . . . .
3.2.3 Protein-Protein Interaction Networks . . . . . .
Pre-processing of Datasets . . . . . . . . . . . . . . . .
3.3.1 Reactive Stroma of Breast Cancer Dataset . . .
3.3.2 LINCS Drug Perturbation Dataset . . . . . . .
3.3.3 Protein-Protein Interaction Network Data Set .
Methodology . . . . . . . . . . . . . . . . . . . . . . .
3.4.1 Hungarian Algorithm . . . . . . . . . . . . . . .
3.4.2 Blossom Algorithm . . . . . . . . . . . . . . . .
3.4.3 Differentially Expressed Subnetwork Method . .
3.4.4 Louvain Community Detection Method . . . . .

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.

Results and Discussion

17
17
19
20
21
21
23
26
28
29
31
32
38
44

Conclusion and Future Work
5.1 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.2 Future Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

49
49
50

REFERENCES

51

VITA AUCTORIS

56

VIII

LIST OF TABLES
3.1

Types of Protein-Protein Interaction . . . . . . . . . . . . . . . . . .

27

3.2

Correlation Table . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

37

4.1

Method1-DES & Method2-LCD . . . . . . . . . . . . . . . . . . . . .

45

4.2

Adverse Effects Drugs . . . . . . . . . . . . . . . . . . . . . . . . . .

46

4.3

Top 31 Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

46

IX

LIST OF FIGURES
1.1

Gene [57] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2

1.2

3D molecular structure of Ibuprofen [3] . . . . . . . . . . . . . . . . .

3

1.3

Drug Repurposing Methods [8] . . . . . . . . . . . . . . . . . . . . . .

5

1.4

Drug Development Cycle [6] . . . . . . . . . . . . . . . . . . . . . . .

7

1.5

Computational Drug Discovery [25] . . . . . . . . . . . . . . . . . . .

9

3.1

Statistics of 2020 cancer data . . . . . . . . . . . . . . . . . . . . . .

17

3.2

GSE26910 Normal & Tumor samples . . . . . . . . . . . . . . . . . .

18

3.3

LINCS L1000 data processing . . . . . . . . . . . . . . . . . . . . . .

19

3.4

Types of biological interactions represented by networks . . . . . . . .

20

3.5

Protein-Protein interaction network . . . . . . . . . . . . . . . . . . .

21

3.6

GSE26910 Dataset . . . . . . . . . . . . . . . . . . . . . . . . . . . .

22

3.7

LINCS Preprocessing Pipeline [5] . . . . . . . . . . . . . . . . . . . .

24

3.8

LINCS data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

25

3.9

p-value per gene based on the z-score data . . . . . . . . . . . . . . .

25

3.10 q-value per gene based on the z-score data . . . . . . . . . . . . . . .

26

3.11 Framework Differentially Expressed [31]

. . . . . . . . . . . . . . . .

29

3.12 Hungarian Algorithm [48] . . . . . . . . . . . . . . . . . . . . . . . .

31

3.13 Edmonds Blossom Algorithm [58] . . . . . . . . . . . . . . . . . . . .

32

3.14 Differentially Expressed Subnetwork Method

. . . . . . . . . . . . .

33

3.15 Framework Overview . . . . . . . . . . . . . . . . . . . . . . . . . . .

34

3.16 Differentially Expressed Subnetwork

. . . . . . . . . . . . . . . . . .

35

3.17 GSE26910-Upregulated & Downregulated . . . . . . . . . . . . . . . .

36

3.18 12 samples breast dataset(Upregulated & Downregulated) . . . . . .

37

3.19 LCD Algorithm

38

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3.20 Framework – LCD Method

. . . . . . . . . . . . . . . . . . . . . . .

3.21 Drug Disease Score Evaluation

. . . . . . . . . . . . . . . . . . . . .

3.22 Drug Disease Network Interaction

X

. . . . . . . . . . . . . . . . . . .

40
41
42

3.23 Adverse Effects [53]

. . . . . . . . . . . . . . . . . . . . . . . . . . .

43

4.1

FDA-approved drugs . . . . . . . . . . . . . . . . . . . . . . . . . . .

47

4.2

FDA-approved drugs . . . . . . . . . . . . . . . . . . . . . . . . . . .

48

XI

LIST OF ABBREVIATIONS

PCA

Principal Component Analysis

PPI

Protein-Protein Interaction

LLE

Locally Linear Embedding

DEG

Differentially Expressed genes

DES

Differentially Expressed Subnetwork

GEO

Gene Expression Omnibus

FDR

False Discovery Rate

XII

CHAPTER 1
Introduction
The process is to go from initial research to an approved drug is a long and expensive process. As a result, the number of new potential drugs has become low and
there are different repurposing approaches that can be categorized as drug-based or
disease-based.

Disease-based approaches are developed to overcome the lack of knowledge about
the pharmacology of a drug. The rise in bioinformatics, where computers are used
to answer biological questions, has reduced the time needed to identify new drug
targets. The known drugs can be put into a computer model to find, if they could
potentially work as a treatment for other diseases. As shown in the Figure 1.1, the
gene is the basic physical and functional unit. Genes are made up of DNA and every
data point generated by a DNA microarray experiment denotes the ratio of expression
levels [18]. The gene expression value will be positive if the production of that gene
is increased in that particular test case and will be negative if the generation of that
gene is decreased instead [19].
Every data point [9] generated by a DNA microarray experiment denotes the
ratio of expression levels. The results from one experiment with n number of genes
on one test subject denote a series of expression levels. In each of these ratios, the
numerator represents the expression level of the gene in a varying condition and the
denominator denotes the expression level of the gene in a reference condition. Data
compiled together to form m such experiments presents a gene expression matrix.

1
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Figure 1.1: Gene [57]

Breast Cancer occurs when the cells in the breast begin to grow out of control
and form a tumor that can be seen on an x-ray or be observable as a lump by
touch. The tumor is malignant (cancer) then the cells can grow into and invade
the surrounding tissues or spread metastasize to distant areas of the body. The
reference dataset is the result of comparing gene expression levels between stroma
surrounding invasive breast primary tumor and matched samples of normal stroma
using Affymetrix Human Genome U133 Plus2.0 Array. This dataset is in GEO(ID:
GSE26910).

1.1

Drug

In pharmacology, a drug [7] is any chemical substance that is administered to living
organisms to generate a biological effect. There are wide variety of drugs, and each
of them are capable of causing different physiological effects [31].
Drug is used to cure a disease and alleviate many symptoms of illnesses. Some drugs
are not used to specifically treat a particular disease but act as a psychoactive chemical
substance influencing a better mood by impacting the central nervous system. A
pharmaceutical drug, also called medication or medicine, is a chemical substance
used to treat, cure, prevent, or diagnose a disease or to promote well-being [2].
2
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Figure 1.2: 3D molecular structure of Ibuprofen [3]

Figure 1.2 shows the 3D molecular structure of a drug known and sold as Ibuprofen
[3], the most common drug in the world.

1.2

Drug Repurposing and Drug Repositioning

Drug Repurposing/Repositioning involves the same procedure but differs on the type
of drug recommended. The unapproved drugs which closely resemble the properties
of approved drugs intended to treat another disease of interest shall be selected as
suitable candidates for drug repositioning, while the approved drugs intended to treat
another disease of interest shall be selected as suitable candidates for drug repurposing.

The drugs used in our research fall under one of the five categories listed below.
• Approved
• Experimental
• Investigational

3
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• Withdrawn
• Unknown
Approved drugs are those that have passed clinical trials. Experimental drugs are
those that have been shown to bind proteins in mammals or bacteria. Investigational
drugs are at one of the phases of the drug design process in one jurisdiction or more.

1.2.1

Drug Repurposing

Drug repositioning (also known as drug repurposing or drug re-profiling) is the process
of redeveloping a compound for use in a different disease. This approach capitalizes
on the fact that approved drugs and many abandoned compounds have already been
tested in humans and detailed information is available on their pharmacology, formulation, dose, and potential toxicity. It is underpinned by the fact that common
molecular pathways often contribute to many different diseases and have many advantages over traditional drug discovery approaches that significantly reduce the cost
and development time.There are various types of approved drugs that have passed
clinical trials. Experimental drugs are those that have been shown to bind proteins
in mammals or bacteria. Investigational drugs are at one of the phases of the drug
design process in one jurisdiction or more. Withdrawn drugs are those that were once
approved but have lost their approval status for any reason. There is not enough data
on unknown drugs as these are in the preliminary stages of drug discovery. When
referring to drugs from various drug categories such as experimental, investigational,
withdrawn, unknown, etc., we shall collectively call these ’unapproved drugs’.
Performing experiments using various methods, we observe that unapproved drugs
display similar properties to those of the approved ones. The unapproved drugs which
closely resemble the properties of approved drugs intended to treat breast cancer shall
be selected as suitable candidates for drug repurposing.

4
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1.2.2

Drug Repostioning

Drug repositioning [8] is the process of finding new therapeutic indications for existing drugs. Drug Repositioning is one best solution for all these side steps of issues.
Drug Repositioning aims at finding new indications for already existing drugs and
therefore increases the available therapeutic choices at a fraction of cost of new drug
development.

It can be an efficient approach to discovery because many existing drugs have
(1) established formulations and manufacturing methods, (2) extensive absorption
distribution, metabolism, excretion, and toxicity data, (3) previously passed clinical
trial safety endpoints and are thus less likely to fail future clinical trials owing to
adverse effects, and (4) phase IV (post-marketing surveillance) safety data, which are
expensive and time-consuming.

1.3

Methods

There are different classifications for Drug Repurposing methods, each of which seeks
to categorize the existing methods depending on some important metrics.

Figure 1.3: Drug Repurposing Methods [8]

Figure 1.3 shows two major drug repurposing approaches are molecular docking
5
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simulation and machine learning. The molecular docking method tries to simulate and
model the physical interactions between the drugs and targets and is used in structural
molecular biology and computer-assisted drug design [8]. Successful docking methods
can efficiently search high-dimensional conformation spaces and accurately rank the
candidate dockings using a scoring function [9]. However, there are some limitations in
the use of molecular docking in drug repurposing. The requirement of known threedimensional (3D) structure of chemical ligands and protein targets severely limits
the application of docking because the structures of many physiologically important
proteins are not fully resolved [10]. Moreover, molecular docking methods demand
significant computational resources resulting in extended run-times [11].
Additionally, because of errors in the determined protein structure, and the incomplete modeling of atomic and molecular interactions, the results of molecular docking
have high false-positive rates [10].
The machine learning method treats drug repurposing as a supervised learning
problem where machine learning algorithms are applied to biological data related
to drugs and then link them to treat specific diseases. Machine learning methods
appear more favorable than docking simulation,as they can examine a larger number
of promising candidates for further experimental screening [11]. Machine learning
methods can be further classified as drug-based, disease-based or data-driven methods
[10]. Drug-based methods try to discover repositioning opportunities by chemical
or pharmaceutical prospective investigation, while disease-based methods focus on
disease management, symptomatically, or pathology.
If more accurate detection of pharmacological properties is needed, drug-based
methods which involve pharmacological or chemical information on drugs may be
preferred. By contrast, disease-based approaches may be preferred when there is
insufficient knowledge of drug pharmacology. Disease-based can be preferred when the
focus is on disease or therapeutic category. Each approach presents unique informatics
challenges, often requiring elements from both drug and disease-based methods to be
incorporated for a successful process [8]. The context in which the drug target works
and can, therefore, help understand the drug mechanisms of action [15].
6
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Network algorithms can readily accomplish tasks such as visualizing various existing interactions, adding newly discovered relationships, and superimposing additional
properties over primary components and their known interactions [16]. Various kinds
of data from different data sets could be represented in one network. Therefore, the
topological properties of the network can be used to make predictions when biological
data is missing and thus reduces the false-positive rates [17].

1.4

Traditional drug discovery

Traditional drug discovery and development procedures are highly time-consuming
and come at a high development cost. Developing a new drug takes about 10 to 17
years and it costs between 500 billion to 2 million dollars[4]. Approximately 90 percent of the newly discovered drugs fail in the clinical trials due to their side - effects
or adverse effects [5] and only one in 10,000 compounds can make it to market, and
less than 20percent of drugs entering Phase II clinical trials succeed[6].

Figure 1.4 shows the various steps involved in traditional drug discovery.

Figure 1.4: Drug Development Cycle [6]

• Step 1: Involves basic research and target identification. Target can be defined
as the pathogen on which the drug is meant to create an effect.
7
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• Step 2: Lead discovery and optimization, which is an initial stage of the drug
discovery process where the small molecules (drugs) are carefully vetted to observe traces of lead compound, a pharmacological chemical.
• Step 3: Examining the dosage level of drugs and ensuring the safety of the
drug. This phase is essential before proceeding to clinical trials. Since a drug
cannot be used on humans without knowing whether it is safe to consume or
not, these trials are conducted on other species that have genetics resembling
human genetics.
• Step 4: Clinical trials are where drugs are tested on humans to study

1.5

Computational drug discovery

Computational drug discovery is an effective strategy for accelerating and economizing
the drug discovery and development process [22]. It includes various aspects of drug
discovery, such as computer programs for designing compounds, tools for systematically assessing potential lead candidates, and the development of digital repositories
for studying chemical interactions [23]. Due to the availability of biological macromolecule and small molecule information, the computational drug discovery has been
extended to most aspects of the drug discovery and development process [24], from
target identification and validation to lead discovery and optimization; these tools
can even be applied to many preclinical trials, which greatly alters the pipeline for
drug discovery and development [25]. As in Figure 1.5 shows a flowchart for the tasks
that have computational approaches applied to and the computational methods used
at each stage.

8
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Figure 1.5: Computational Drug Discovery [25]

1.6

Problem Statement

Given drug perturbation data and gene expression data for breast cancer, we aim to
obtain a ranked list of drugs that would make suitable candidates for drug repurposing and drug repositioning for the breast cancer dataset. Find the ranked list
of drugs that make suitable candidates for drug repositioning for the disease breast
cancer using network-based drug repositioning method and to find the adverse effects
of such drugs.

We integrate information from different sources such as molecular interaction networks like Protein-Protein Interaction networks (PPI) with the gene expression profiles for a strong Drug Repurposing/Repositioning. We then make use of machine
learning methods such as using the Louvain Clustering Algorithm and detect community networks and obtain a disease-drug data network. Finally, we propose Edmond’s matching algorithm to obtain the best-suited drug that could be repurposed
for breast cancer disease.

9
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1.7

Thesis Motivation

The main goal of computational drug repurposing methods is to find new indications
for approved drugs, systematically. This method explores the anti-similarity between
drugs and a disease to uncover new uses for the drugs. Researching the repurposing of
unapproved drugs sharing similarities with approved drugs intended to treat breast
cancer would help speed up the drug design process involving drug discovery and
development phases. As a result, years and billions of dollars will have been conserved
to help cure breast cancer disease. Most importantly, this thesis does its part in
helping us move one step closer to acquiring suitable drugs to tackle breast cancer.

1.8

Thesis Contribution

In this thesis, we propose an application to identify the Differentially Expressed Subnetwork that could help us in finding the best candidate drugs for repurposing on
all breast cancer subtypes to obtain a ranked list of suitable drug repurposing and
repositioning. Then, we propose using Hungarian and Edmond’s matching algorithm
to obtain the best-suited drug that could be repurposed for breast cancer disease.
Finally, we will find out the adverse effects of drugs based on the top 10% of drugs
from the drugs lists obtained by applying the proposed methods on the breast cancer
datasets. Ranked according to the repurposing scores from the highest to the lowest.

1.9

Thesis Organization

The rest of the thesis/ research work is organized in the following manner.
• Chapter 2, discuss a literature review in the area of drug repurposing using
computational approaches.
• Chapter 3, introduce our proposed approach and explain all the techniques used
to obtain suitable drug repurposing candidates for the breast cancer dataset.

10
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• Chapter 4, present the experimental results and perform an analysis of those
results.
• Chapter 5 concludes the research by explaining insights received during the
work and setting up the field of opportunities for possible future work.

11

CHAPTER 2
Literature Review

2.1

Introduction

This chapter consists of some literature reviews regarding computational drug repurposing using various disease data. Several computational approaches for drug
repurposing have been developed that are worth noting and we discuss some of those
works below.

2.1.1

A Network Approach for Computational Drug Repositioning

This paper is based on the hypothesis that a drug can be repositioned to another
drug’s curing area if two drugs share similar molecular and/or chemical properties.
The authors of this paper, Li, Jiao & Lu, Zhiyong [27] constructed a disease-drugtarget network based on prior knowledge (i.e., known therapeutic uses of drugs and
known drug targets). Different from the other similarity-based methods, in drug
pairwise similarity calculation, the authors have adapted a novel bipartite-graphbased method to represent the relationships between drugs and their target proteins
as a bipartite graph. Furthermore, they added the drug structure information into the
drug pairwise similarity calculation and in this way, their method boosts the target
similarity by making use of their corresponding interaction information. Then, the
drug pair with a higher similarity score is predicted to be repurposed to each other
therapeutic area.

12
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2.1.2

A new computational drug repurposing method using
established disease-drug pair knowledge

The paper is based on the method that if a drug-exposure gene expression profile
inversely correlates with a disease gene expression profile, the drug may have a therapeutic effect on the disease. The authors of this paper, Nafiseh Saberian, Azam
Peyvandipour, Michele Donato, Sahar Ansari, and Sorin Draghici [28] at first formed
an input matrix by combining the reversed measurements of the genes in the disease profile and the measurements of the same genes in each of the drug profiles.
Their workflow consists of transforming the input matrix into a lower dimensionality matrix by incorporating dimensionality reduction techniques such as principal
component analysis (PCA) or Locally Linear Embedding (LLE). Then the authors
have used the known relationship between disease and its FDA-approved drugs into
a transformed space using a distance metric learning algorithm. In this process, the
clinically relevant drugs get close to the disease and the Euclidean distance between
the disease gene expression profile and each of the drug-exposure expression profiles
is calculated. Then the drugs are ranked based on the closest to the farthest distance
from the disease.
The authors of this paper have worked towards obtaining drug repurposing candidates for three diseases: breast cancer, rheumatoid arthritis, and idiopathic pulmonary fibrosis. They have used GEO disease data for breast cancer, CMAP data
for rheumatoid arthritis, and LINCS for idiopathic pulmonary fibrosis.
The authors of this paper have made use of only the transcriptional data, so
the results are not much reliable. Incorporating transcriptional data with available
clinical knowledge such as drug, chemical and disease biomarkers could yield better
results.
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2.1.3

A novel computational approach for drug repurposing
using systems biology

The authors of this paper, Azam Peyvandipour, Nafiseh Saberian, Adib Shafi, Michele
Donato, and Sorin Draghici [29] built a global network (GN) which is the union of
all KEGG human signaling pathways. Then a subgraph was extracted from the
global network comprising of the shortest paths between the disease-related genes
and drug targets and termed it drug-disease network (DDN). Then a system-level
analysis was applied to the gene expression signatures of drug-disease pairs to generate
gene perturbation signatures in the drug-disease network. Further, the authors have
assigned a repurposing score on the drug-disease pair and obtained a ranked drug
list with potential therapeutic effects for the given disease based on the repurposing
scores. The limitation of this paper is that the gene regulatory network constructed
in the proposed method is biased due to the existence of noise in the gene expression
data.

2.1.4

Drug repositioning for cancer therapy based on largescale drug- induced transcriptional signatures

The authors of this paper, Haeseung Lee, Seungmin Kang, and Wankyu Kim [30]
have developed a series of seven classifiers using logistic regression to predict drug repurposing candidates for the treating of glioblastoma, lung cancer, and breast cancer.
They make use of signatures obtained from the chemical structure (S), drug-target
relation (T), and gene expression data (E). Suitable drug repurposing candidates
were predicted based on the similarity of the signatures between the compounds and
disease or known drugs. The limitation of this method is that the method considers
only Differentially Expressed genes (DEG) in the drug dataset. DEG’s in the disease
dataset are not taken into consideration and structures for most of the drugs are not
available.
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2.1.5

Breaking the paradigm: Dr Insight empowers signature free, enhanced drug repurposing

The authors of this paper, Jinyan Chan, Xuan Wang, Jacob A Turner, Nicole E Baldwin, and Jinghua Gu [31] have developed a signature free, optimal drug repurposing
based on gene expression data, namely Dr.Insight which overcomes the limitations
of the existing computational frameworks. The method considers the dysregulation
of gene expression from both disease and drug-perturbed data simultaneously, which
renders the DEG’s as optimal features to investigate the connections among diseases,
drugs, and genes. The authors have done an extensive comparison on simulated and
real cancer datasets and validated the superior performance of Dr. Insight over several popular drug-repurposing methods to detect known cancer drugs and drug-target
interactions.

In above all mentioned literature surveys, we found that all the papers were using
bioinformatic methods that focus on identifying biomarkers as small subsets of differentially expressed genes that are limited to predictive and insufficient patient sample
size, inherent measurement noise in microarray experiments make the biomarkers unstable [42]. Also, computational methods detecting differentially expressed genes do
not consider the dependencies or relationships between genes to accurately classify the
sample data, thus identified biomarker set may contain many differentially expressed
genes with redundant information yielding decreased prediction performance. So, to
accurately identify effective biomarkers, new bioinformatic methods integrating additional biological information with gene expression data have become necessary [31].
In this thesis, we aim to identify a differentially expressed subnetwork (DES) as an
effective biomarker that could help us to find the best candidate drugs for repurposing
as well as to find out the adverse effects of such drugs.
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CHAPTER 3
Proposed Methods

3.1

Introduction

In this chapter, we discuss the datasets, pre-processing steps taken, and machine
learning techniques used in this thesis.

3.1.1

Breast Cancer

Cancer occurs as a result of mutations, or abnormal changes, in the genes responsible
for regulating the growth of cells and keeping them healthy. A tumor can be benign
- not dangerous to health or malignant - has the potential to be dangerous. Breast
cancer is a disease in which cells in the breast grow out of control [20]. Usually, breast
cancer either begins in the cells of the lobules, which are the milk-producing glands,
or the ducts.

3.1.2

Why Breast Cancer?

Breast Cancer makes up quarterly of all new cancer diagnoses in women across the
globe according to the American Cancer Society(ACS) [21].
As shown in the Figure 3.1, the estimated statistics of 2020 cancer data clearly depicts the need for an effective drug to cure the breast cancer among women. Moreover,
breast cancer is the second leading cause of death due in Canadian women.
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• 26,900 women will be diagnosed with breast cancer. This represents 25 percent
of all new cancer cases in women in 2020.
• 5,000 women will die from breast cancer. This represents 13 percent of all cancer
deaths in women in 2020.
• On average, 74 Canadian women will be diagnosed with breast cancer every day
and on average, 14 Canadian women will die from breast cancer every day.

Figure 3.1: Statistics of 2020 cancer data

3.2
3.2.1

Datasets
Reactive Stroma of Breast and Prostate Cancer

The disease data titled “Reactive Stroma of Breast and Prostate Cancer” was obtained
from the National Center for Biotechnology Information’s (NCBI), Gene Expression
Omnibus (GEO) portal.
GEO is a public repository that archives and freely distribute comprehensive sets
of microarray, next-generation sequencing, and other forms of high-throughput functional genomic data submitted by the scientific community. This dataset consists of
gene expression data for a large pool of breast cancer genes. The dataset consists of
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stroma associated with prostate and breast invasive tumors. It consists of 24 samples
which include, six samples of stroma surrounding invasive breast primary tumors,
six samples of stroma surrounding invasive prostate primary tumors and six matched
samples of normal stroma for each type of tumour where this stroma refers as the
part of a tissue or organ that has a structural. Out of this, we extracted the 6 samples
of breast cancer stroma and six matched samples of normal stroma related to breast
cancer. The dataset consisted of 12 columns and 20,322 genes.
Lets take a sample GSE26910 dataset and identify genes that are differentially
expressed across experimental conditions. The result as presented as below in Figure
3.2;

Figure 3.2: GSE26910 Normal & Tumor samples
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3.2.2

LINCS

The drug data was extracted from the pharmacogenomics perturbation data which
is the National Institute of Health’s (NIH) Library of Integrated Network- Based
Cellular Signatures (LINCS) dataset. This dataset consists of 21,567 drugs in the
columns and 12,328 genes in the rows. This dataset is a level 5 LINCS dataset and
consists of normalized z-score values. Level 4 LINCS data consists of two sets of data,
before administration of drugs and after administration of drugs onto the genes in
the dataset. These expression values from both the level 4 datasets are normalized
to form the level 5 LINCS dataset.

Figure 3.3: LINCS L1000 data processing

Figure 3.2 depicts L1000 data is provided at five levels of the data processing
pipeline [32]:
• Level 1: Raw unprocessed flow cytometry data from Luminex (LXB).
• Level 2: Gene expression values per 1000 genes after deconvolution (GEX).
• Level 3: Quantile-normalized gene expression profiles of landmark genes and
imputed transcripts (Q2NORM or INF).
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• Level 4: Gene signatures computed using z-scores relative to the plate population as control (ZSPCINF) or relative to the plate vehicle control (ZSVCINF).
• Level 5: Differential gene expression signatures.

3.2.3

Protein-Protein Interaction Networks

Proteins are large biomolecules, or macromolecules, consisting of one or more long
chains of amino acid residues. The roles of proteins are many and varied. Protein,
DNA, RNA, and other biological molecules do not work in isolation; they cooperate
with other proteins to perform a biological activity. Two molecules that cooperate to
perform a function are said to be interacting. It is the combination of these molecules
and their interactions, and not the molecules alone, that characterize the mechanisms
of a biological process.

Figure 3.4: Types of biological interactions represented by networks

Figure 3.3 shows Protein–Protein Interactions (PPI’s) which are the physical contacts of high specificity established between two or more protein molecules as a result
of biochemical events steered by electrostatic forces including the hydrophobic effect.
This Protein-protein Interactions (PPI) can be modeled as networks and each protein
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is represented as a node, and an edge between any two nodes indicates that these two
proteins interact.
Figure 3.4 [37] shows an example of Protein-Protein Interaction networks, where
the proteins are represented by nodes.

Figure 3.5: Protein-Protein interaction network

The STRING database contains information on about 9.6 million proteins from
more than 2000 organisms [40].

3.3

Pre-processing of Datasets

The pre-processing pipeline used on the datasets to be used in the machine learning
methods in this thesis is explained in the following subsections.

3.3.1

Reactive Stroma of Breast Cancer Dataset

The statistical scores such as p-value, FDR-corrected p-value (or q-value), and Zscores were calculated using the sick and the healthy samples of the breast cancer
disease dataset. Having the possibility of there being a large number of false positives
is not statistically good and so we calculate the q-values using the False Discovery
Rate (FDR) approach.
The False Discovery Rate (FDR) is a method of conceptualizing the rate of type I
errors (rejection of a true null hypothesis) in null hypothesis testing when conducting
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multiple comparisons. The older approaches reduced the number of false positives
while also reducing the number of true positives which is not optimal. This newer
FDR approach gives us adjusted p-values in every test case. In simpler terms, the pvalue predicts that there could be 5% false positives in the entire list of Differentially
Expressed Genes (DEG) whereas the q-value (FDR-adjusted p-value) predicts that
there could be 5% false positives in the significant tests.
Lets take the GSE26910 dataset and identify genes with P-values across experimental
conditions. The result as presented as below in Figure 3.6;

Figure 3.6: GSE26910 Dataset
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The false discovery rate formula is [34] :

F DR = E(V /R | R > 0)P (R > 0)
Where,
• V = Number of Type I errors (i.e. false positives)
• R = Number of rejected hypotheses
q-values are the name given to the adjusted p-values found using an optimized
FDR approach. The FDR approach is optimized by using characteristics of the pvalue distribution to produce a list of q-values. For the breast cancer dataset, the
genes having FDR-corrected p-value < 0.05 were the Differentially Expressed Genes
(DEG). Out of 20,322 genes in the breast cancer dataset, 138 genes were identified
to be differentially Expressed.
The LINCS database has 12,328 gene expression profiles. For each gene, we calculate the p-value based on the z-score and eliminate datasets that FDR-corrected
p-value < 0.05 genes.

3.3.2

LINCS Drug Perturbation Dataset

The LINCS drug dataset consists of drugs related to 7 cell lines. Out of 7 cell lines,
we have extracted drugs belonging to the cell line MCF7. This way we have multiple
entries of most drugs, so we have filtered them based on the dosage and time under
administration. Within this cell line, we have filtered drugs whose dosage was 1.11um
and whose time under administration was 24 hours.
Out of 21,567 drugs, 1844 drugs passed our criteria. Then we computed p-values
based on the z-score by using the normal distribution and FDR corrected p-value(qvalue) for each gene per drug profile to select the statistically significant values [35].
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Figure 3.7 [5] explains the LINCS pre-processing pipeline. Like the disease dataset,
the genes having FDR corrected p-value < 0.05 were considered to be differentially
expressed.

Figure 3.7: LINCS Preprocessing Pipeline [5]

Here, we find q-values,p-values, and Z-core values to find the significant result.
q-values are the name given to the adjusted p-values found using an optimized FDR
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approach. The FDR approach is optimized by using characteristics of the p-value
distribution to produce a list of q-values. We compute p-values for each gene per
drug profile to select the statistically significant values [1]. The cut off set here is
0.05 which means that there is a 5% chance that we are choosing a false positive
among the list of DE genes. Having the possibility of there being a large number
of false positives is not statistically good and so we calculate the q-values using the
false discovery rate (FDR) approach. The older approaches reduced the number of
false positives while also reducing the number of true positives which is not optimal.
This newer FDR approach gives us adjusted p-values in every test case. In simpler
terms, p-value predicts that there could be 5% false positives in the entire list of DE
genes whereas q-value (FDR-adjusted p-value) predicts that there could be 5% false
positives in the significant tests. Significant tests are those values that are deemed to
be true positives based on the p-value.
As shown in Figure 3.8, LINCS data representation clearly shows how the various
genes and drugs are related to each other based on the z-score values.

Figure 3.8: LINCS data

Figure 3.9: p-value per gene based on the z-score data
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Figure 3.9 shows, how the p-value per gene is calculated based on the z-score data
and Figure 3.10, shows how to proceed to calculate the q-value per gene and discard
those drug profiles which contain less than 1% DE (differentially expressed) genes.

Figure 3.10: q-value per gene based on the z-score data

Here we have extracted the drugs belongs to the cell line ”MCF7”. This way we
have multiple entries of most drugs so we have filtered them based on the dosage and
time under administration. Within this cell line, we have filtered drugs whose dosage
was 1.11um and whose time under administration was 24h. This has enabled us to
select unique instances of all drugs fitting our criteria.

3.3.3

Protein-Protein Interaction Network Data Set

We obtained the directed protein-protein interaction network by combining protein
interactions from the “Pathway Commons Protein-Protein Interactions database” and
the “STRING” database. Table 3.1 shows, the PPI’s [5] in the Pathway Commons
database.

We extracted the interaction from the Pathway Commons Protein-Protein Interactions database with the interaction types in “controls-expression-of, controls-statechange-of, controls-phosphorylation-of, and catalyses-precedes”.
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Table 3.1: Types of Protein-Protein Interaction
Interaction Types

Description

controls-state-change-of

First protein controls a reaction that
changes the state of the second protein

controls-transport-of

First protein controls a reaction that
changes the cellular location of the second protein.

controls-phosphorylation-of

First protein controls a reaction that
changes the phosphorylation status of
the second protein.

controls-expression-of

First protein controls a conversion or a
template reaction that changes expression of the second protein.

catalysis-precedes

First protein controls a reaction whose
output molecule is input to another reaction controlled by the second protein

in-complex-with

Proteins are members of the same complex.

interacts-with

Proteins are participants of the same
Molecular Interaction.

neighbor-of

Proteins are participants or controlers of
the same interaction.

consumption-controled-by

The small molecule is consumed by a reaction that is controled by a protein

controls-production-of

The protein controls a reaction of which
the small molecule is an output.

controls-transport-of- chemical

The protein controls a reaction that
changes cellular location of the small
molecule.

Then, we extracted the directed interactions from the STRING database. The
confidence score of an interaction in the STRING database is defined as the approximate probability that a predicted link exists between two enzymes in the same
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metabolic map in the KEGG database. Confidence limits are as follows:
• low confidence - 0.25 (or better),
• medium confidence - 0.4,
• high confidence - 0.7
• highest confidence - 0.9
We removed all the interactions with weak confidence, with score less than 0.25.
The duplicate interactions were removed, and the PPI network was formed by combining interactions from the “Pathway Commons Protein-Protein Interactions database”
and “STRING” database. PPI network comprises 904284 unique interactions.

3.4

Methodology

In this thesis, we have proposed two methodologies to find the ranked list of drugs that
would make suitable candidates for Drug Repositioning/Repurposing for the disease
of breast cancer. We formed the breast network data from the PPI network by
considering only the genes present in the breast disease data and the disease network
data consist of 716,426 unique interactions. Then, we constructed the drug network
data from the PPI network, for each drug profile by considering only the differentially
expressed genes present in each drug profile of the drug data and obtained 110 drug
networks.
In the first method, we aim to find a Differentially Expressed Subnetwork (DES) from
the disease network data. A gene is declared differentially expressed if an observed
difference or change in reading counts or expression levels between two experimental
conditions is statistically significant [52].
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Figure 3.11: Framework Differentially Expressed [31]

Figure 3.9 shows, a Differentially Expressed subnetwork (DES) which is a diseaserelated subnetwork of differentially expressed interacting genes identified by appropriate integration of secondary network data with the primary gene expression data.

In our second method, we use community detection algorithms to find the communities or clusters in the disease and the drug network data. Community detection
in networks is one of the most popular topics of modern network science. Communities or clusters are usually groups of vertices having a higher probability of being
connected than to members of other groups, though other patterns are possible [44].

3.4.1

Hungarian Algorithm

The standard assignment problem is referred to as the problem to find a one-to-one
matching between tasks and agents, to optimize the total cost of the assignments.
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The objective is either to maximize or minimize the total cost. In this thesis, we wish
to find the optimal assignment of a rank of drugs, by maximizing the total cost. The
classical example of assignment problems is assigning jobs to workers. Hungarian
method is the most popular method which solves the assignment problem in polynomial time. It was developed and published by Harold Kuhn in 1955 [48].

The Hungarian Method is based on the principle that if a constant is added to
every element of a row and/or a column of the cost matrix, the optimum solution of
the resulting assignment problem is the same as the original problem and vice versa.
The original cost matrix can be reduced to another cost matrix by adding constants
to the elements of rows and columns where the total cost or the total completion time
of an assignment is zero. Since the optimum solution remains unchanged after this
reduction, this assignment is also the optimum solution of the original problem [48].

The Hungarian algorithm consists of the four steps:
• Step 1 (Subtract row minima): In the cost matrix, for each row, the lowest
element is subtracted from each element in that row.
• Step 2 (Subtract column minima): Similarly, for each column, the lowest element is subtracted from each element in that column.
• Step 3 (Cover all zeros with a minimum number of lines): Then all the zeros
in the resulting matrix are covered using a minimum number of horizontal and
vertical lines. If n lines are required, an optimal assignment exists among the
zeros. The algorithm stops. If less than n lines are required, Step 4 is continued.
• Step 4 (Create additional zeros): The smallest element (call it k) that is not
covered by a line in Step 3 is subtracted from all uncovered elements and k is
added to all elements that are covered twice.
Figure 3.9 shows, how to find the optimal assignment of a rank of drugs, by
maximizing the total cost.
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Figure 3.12: Hungarian Algorithm [48]

3.4.2

Blossom Algorithm

The Blossom Algorithm is used for finding the maximum matching in a graph, through
the Blossom contraction process. This polynomial-time algorithm is used in many
applications including the assignment problem, the marriage problem, and the Hamiltonian cycle and path problems (i.e., Traveling Salesman Problem). This obtains the
potential best-suited drugs with help of Edmonds matching algorithm. It proves the
number of iterations that must go through to find the maximum flow of a network.

The algorithm improves the Hungarian algorithm by shrinking cycles in the graph
to reveal augmenting paths. Moreover, the Hungarian algorithm can only work on
weighted bipartite graphs whereas the blossom algorithm will work on any graph.

The algorithm will calculate the wrong augmenting path because it will miss some
of the edges from the calculation. Additionally, a cycle makes the algorithm loop reducing the minimum-weight optimization. The Blossom algorithm aims to fill this
gap by solving more generalized graph matching problems and can be used when the
graph is not guaranteed to be bipartite.
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This algorithm improves the Hungarian algorithm by having a way to deal with
odd-length cycles. This is done by finding a way the trick the algorithm into thinking
it is operating on a simple bipartite graph, collapsing a cycle into a single vertex, so
it can run the Hungarian algorithm on the matching [58]. As shown in Figure 3.10,
it helps to find the maximum matching in a graph, through its contraction process.

Figure 3.13: Edmonds Blossom Algorithm [58]

3.4.3

Differentially Expressed Subnetwork Method

In biological studies, a biomarker is a measurable indicator of the severity or presence
of some disease state. More generally a biomarker is anything that can be used as an
indicator of a particular disease state or some other physiological state of an organism
[41]. In the literature survey, we found that all the papers were using bioinformatic
methods focus on identifying biomarkers as small subsets of differentially expressed
genes. Differentially expressed genes (DEG’s) have limited predictive performance
due to the heterogeneity within tumor samples and across patients, moreover, insuf-
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ficient patient sample size and the inherent measurement noise in microarray experiments make the biomarkers with DEG’s unstable [42]. Also, computational methods
detecting DEGs do not consider the dependencies or relationships between genes to
accurately classify the sample data, thus identified biomarker set may contain many
DEGs with redundant information yielding decreased prediction performance. As
shown in Figure 3.11 explains the process of finding the Differentially Expressed Subnetwork (DES).

Figure 3.14: Differentially Expressed Subnetwork Method

Figure 3.12 represents, the proposed framework which involves finding the Differentially Expressed Subnetwork (DES). We have obtained the Differentially Expressed
Subnetwork (DES) with the help of the breast network data and the Differentially
Expressed Genes (DEG) of the disease data. The Differentially Expressed subnetwork (DES) is obtained for each of the DEGs in the disease data, so 138 Differentially
Expressed Subnetwork (DES) is obtained.
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Figure 3.15: Framework Overview

Figure 3.13 depicts the Differentially Expressed Subnetwork (DES) formation with
starting from a DEG V, the search for the Differentially Expressed Subnetwork proceeds as follows:
• The current aggregate N initially contains only the differentially Expressed gene
V.
• We iteratively aggregate its neighbor nodes U in a greedy manner using BreadthFirst Search Algorithm.
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• A neighbor u is inserted into the current aggregate N if and only if its inclusion
increases the correlation between the expression of the genes in the aggregate.
| correlation(N + u)correlation(N ) |> 4, where 4 is 0.001
• Then, the same process is repeated on the new aggregate N + u and the process
continue till the level 2 neighbors are evaluated.

Figure 3.16: Differentially Expressed Subnetwork

After obtaining the Differentially Expressed Subnetwork (DES), the next step
was to check for the correlation of genes, between each of the Differentially Expressed
Subnetwork (DES) and the drug data.

For each Differentially Expressed Subnetwork(DES), a percentage score is given
based on the total number of genes that are directly correlated between the DES and
the drug data i.e. if no genes are directly correlated between a DES and the drug
data, then it is scored 0 and if all the genes are adversely correlated then it is scored
100. Then finally Hungarian Algorithm is applied to the obtained score matrix to
get the ranked list of drugs that act as the potential candidate for drug repurposing/repositioning.
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Figure 3.17 shows, dataset GSE26910 for of breast cancer data, we could identify the upregulated and downregulated genes with respect to p-value after the null
hypothesis test.

Figure 3.17: GSE26910-Upregulated & Downregulated
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Table 3.2: Correlation Table
As shown Figure 3.18, 12 samples of upregulated and downregulated genes of
breast cancer dataset.

Figure 3.18: 12 samples breast dataset(Upregulated & Downregulated)

Table 3.2 shows the anti-correlation labels and the correlation which makes the
drug, a suitable candidate for repurposing. Down-regulation indicates a decrease in
the production of that gene as an effect of the disease. Up-regulation indicates an
increase in the production of that particular gene as an effect of the disease.
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3.4.4

Louvain Community Detection Method

The second method used as a community detection algorithm on the disease network
data followed by correlation analysis to find the repurposing score and the combinatorial optimization algorithm to rank the drugs, based on the repurposing score.
We finally have a list of drugs ranged from potentially best-suited drug repurposing
candidates for the disease breast cancer to potentially less effective drug repurposing
candidates. There are different types of algorithms used for community detection.
In this thesis, we have used the Louvain community Detection Method (LDM) for
detecting communities in networks [55].

Figure 3.19: LCD Algorithm
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As shown in Figure 3.15, the LCD algorithm list the drugs ranked from potentially
best suited drug repurposing candidates for the disease breast cancer to potentially
less effective drug repurposing candidates.The Louvain method for community detection is an algorithm used for detecting where the modularity quantifies the quality of
an assignment of nodes to communities. Modularity is defined as a measure of the
structure of networks or graphs. It is designed to measure the strength the division
of a network into modules (also called groups, clusters, or communities) [45].
• The Louvain algorithm starts from a singleton partition in which each node is
in its community. The algorithm moves individual nodes from one community
to another to find a partition.
• Based on the obtained partition, an aggregate network is created.
• The algorithm then moves individual nodes in the aggregate network.
• These steps are repeated until the quality cannot be increased further.
Figure 3.16 shows, the second method used as a community detection algorithm
on the disease network data followed by correlation analysis to find the repurposing
score and the combinatorial optimization algorithm to rank the drugs, based on the
repurposing score. We finally have a list of drugs ranged from potentially best-suited
drug repurposing candidates for the disease breast cancer to potentially less effective
drug repurposing candidates.
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Figure 3.20: Framework – LCD Method

The algorithm optimizes a quality function such as modularity in two elementary
phases. The first phase involves the local moving of nodes and the second phase
involves the aggregation of the network. In the local moving phase, individual nodes
are moved to the community that yields the largest increase in the quality function.
In the aggregation phase, an aggregate network is created based on the partition
obtained in the local moving phase. Each community in this partition becomes a
node in the aggregate network. The two phases are repeated until the quality function
cannot be increased further [47].
We applied the Louvain community detection algorithm on the breast network
data and obtained 14 communities. Then the correlation analysis was performed on
each of the drug network data and the corresponding disease network communities.
In this method, we have computed two repurposing scores based on the correlation.
In the first case, Figure 3.18 shows the score which is computed based on the total
number of genes that are correlated between each of the breast network communities
and the drug networks. Figure explains the computation of the adversely correlated
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gene score. Circle A consists of the disease genes, and circle B consist of the drug
genes. Genes A, B, D, and G are in common between the disease and the drug genes.
Among the common genes, the genes which are adversely correlated are highlighted
in red color. These adversely correlated common genes are used to calculate the first
score.

Figure 3.21: Drug Disease Score Evaluation
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Figure 3.22: Drug Disease Network Interaction

In the second case, Figure 3.19 shows how the score was computed on the basis
of a number of various interactions between the breast network communities and the
drug networks. Finally, we find the best suited drugs which has adverse effects using
the Reporting Odds Ratio (ROR) measure is defined by the formula below [53];
ROR = (a.d)/(c.b)

(1)

Where:
• The value “a” indicates the number of DEG in both drug and disease;
• The value “b” indicates the number of DEG in the drug P but not in the disease
data;
• The value “c” indicates the number of DEG in the disease but not the target
drug data P;
• The value “d” indicates the number of DEG which do not list both the target
disease data or in the target drug data P
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Figure 3.20, depicts the similar drugs that shown adverse effects in previous
study that which exactly shows the three drugs from our result set such as Docetaxel, Paclitaxel and Doxorubicin.

Figure 3.23: Adverse Effects [53]
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CHAPTER 4
Results and Discussion

In this thesis, we could find various result set of both the proposed methods
for the disease of Breast Cancer and compare the results obtained. The results
showcase several unapproved drugs alongside approved drugs closest to the disease indicating that the unapproved drugs share similarities with the approved
drugs which means that they are worth pursuing repurposing. Similarly various FDA Approved drugs shows different adverse effects which lead to many
diseases in future.

The following tables show the ranked top 10 drugs and 30 drugs for the disease
breast cancer obtained using our proposed methods. Initially, we have selected
the top 10% of drugs by applying the proposed methods on the breast cancer
datasets. These drugs are ranked according to the repurposing scores computed by the systematic method from the highest to the lowest. We have used
online drug databases such as Drug Bank [49] to obtain each drugs’ FDA status.

Table 4.1, shows the list of ranked drugs obtained by the DES method and
LCD method. The ranked list of drugs obtained from both the LCD method
and DES for the disease of breast cancer comprises 8 approved drugs and 2
unapproved drugs. Approved drugs are highlighted in green and unapproved
drugs from both the method are highlighted as white. Among those approved
drugs, Docetaxel, Paclitaxel, Taxmoxifen, and Doxorubicin show adverse effects
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Table 4.1: Method1-DES & Method2-LCD
based on two methods.
Table 4.2 shows top 10 adverse effect drugs that are Approved and Investigational by FDA;
Tamoxifen, Gemcitabine, Epirubicin, Exemestane, Capecitabine, Paclitaxel,
Doxorubicin, gemcitabine, Fulvestrant, Exemestane, Neratinib, Docetaxel are
some of the FDA approved drugs for the disease breast cancer. These drugs
were included in our list of input drugs from the LINCS drug dataset to validate
our proposed methods.

Table 4.3 shows the validation results for the top 31 FDA-approved drugs for
the different categories the disease of breast cancer are highlighted in green
colour.
For breast cancer and prostate cancer, these are the various FDA-approved
drugs that have been highlighted in red. The rest of the drugs are in advanced
clinical trials [55].
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Table 4.2: Adverse Effects Drugs

Table 4.3: Top 31 Drugs
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Figure 4.1 shows the various FDA-approved drugs which we have used in our
research study;

Figure 4.1: FDA-approved drugs

This Figure 4.2 shows the few FDA Approved Drugs(Drug Target Network) [56];
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Figure 4.2: FDA-approved drugs
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CHAPTER 5
Conclusion and Future Work

5.1

Conclusion

In this thesis, the main goal of computational drug repurposing methods is to find
new indications for approved drugs, systematically. We performed a series of preprocessing steps on both of these datasets. This method explores the anti-similarity
between drugs and a disease to uncover new uses for the drugs. Different types algorithm such as Hungarian, Edmonds Blossom techniques can retrieve the best suited
FDA-approved drugs for their approved indications and Using Louvain Clustering
Algorithm, we detect communities in networks. Once validated, we used Reporting
Odds Ratio approach to identify a Adverse drug Effect on Breast Cancer.
• Find suitable drug repurposing candidates for the disease of breast cancer using
the Network-based method. We used Reactive Stroma of Breast and Prostate
cancer disease datasets, LINCS drug datasets, and the Protein-Protein Interaction (PPI) networks from the “Pathway Commons Protein-Protein Interactions
database” and the “STRING” database. We performed a series of pre-processing
steps on these datasets and proposed two different methods for achieving the
drug repurposing/repositioning for the disease of breast cancer. In our first
method, we have discussed methods to identify a Differentially Expressed Subnetwork (DES) as an effective biomarker that helped us to find the best candidate drugs for repurposing. We also discussed the ABC model of Network-based
drug repurposing/repositioning.
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5. CONCLUSION AND FUTURE WORK

• Proposed an efficient method for Adverse Drug Effects
• Proposed a pipeline approach by applying the proposed methods on the breast
cancer datasets and drug datasets. These drugs are ranked according to the
repurposing scores computed by the systematic method from the highest to
the lowest. We have used online drug databases such as drug Bank [49] to
obtain each drugs FDA status. The list of various ranked drugs obtained by
the DES method and ROR. The ranked list of drugs obtained from both DES
and LCD method for the disease of breast cancer comprises approved drugs and
unapproved drugs.

5.2

Future Work

This thesis is just a small step towards drug repurposing and drug repositioning.
Future work that can be conducted include the pre-processing steps and methods can
be applied on a different cancer dataset such as prostate cancer. These ideas can be
an open problem that can be explored in the future.
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